Navigation Links
Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress
Date:8/4/2009

dy that summarized the gene signatures of male patients for whom the Oncotype DX breast cancer test was used to guide chemotherapy treatment indicating that breast cancer in men displays similar gene signatures to female breast cancer.
  • Study results demonstrating that there were significant differences in gene expression between triple negative breast cancer and hormone receptor-positive disease, including genes for which targeted agents are currently being evaluated in clinical studies.
  • Product Pipeline

    • Presented positive results from the landmark QUASAR colon cancer validation study at the 2009 ASCO annual meeting. Results demonstrated that the Oncotype DX colon cancer test can independently predict individual recurrence risk for stage II colon cancer patients following surgery. Importantly, the Oncotype DX colon cancer Recurrence Score(R) provided additional independent clinical value beyond standard measures.
    • Completed processing samples for our renal cancer gene identification study with the Cleveland Clinic and Pfizer.

    Patents

    • Were granted two new U.S. patents for the Oncotype DX breast cancer test covering methods for the algorithms used and methods utilizing genes beyond the current 21 gene set.
    • Were granted a patent by the European Patent Office providing rights to monitor gene expression using intronic regions of genes.

    Conference Call Details

    To access the live conference call today, August 4, at 4:30 p.m. Eastern Time via phone, please dial (877) 361-8830 from the United States and Canada or +1(706) 679-8297 internationally. The conference ID is 22377396. Please dial in approximately ten minutes prior to the start of the call. A te
    '/>"/>

    SOURCE Genomic Health, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Transgenomic, Inc. Reports Second Quarter 2007 Results
    2. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
    3. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
    4. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
    5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
    6. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
    7. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
    8. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
    9. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
    10. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
    11. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... device," Nobel laureate Herbert Kroemer famously observed, referring ... the junctures where layers of different materials meet. ... between layers of metal oxides are becoming increasingly ... spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing the ...
    (Date:1/15/2014)... Jan. 15, 2014   Niagara Thermal Products is ... Buffalo BioBlower Technologies LLC ("B3") as the critical thermal ... award from the Army Corps of Engineers.  B3 has ... all biological contaminants and destroys VOCs and other chemical ...
    (Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... for cancer, today announced the appointment of Thomas C Reynolds ... over 20 years, development experience gained in the biotechnology industry, ... "I am delighted to welcome Tom at this transformative ...
    (Date:1/15/2014)... A study has been launched to test whether ... could help to tackle the problem of obesity.  This unique ... surgery based in Stowmarket) and academics at University Campus Suffolk ... technology, which is inspired by equipment used to collect data ...
    Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
    ... 19, 2011 OptiScan Biomedical Corporation, a developer ... in intensive care units (ICU), today announced that ... has received CE Mark certification for use in ... the OptiScanner has met all relevant European Union ...
    ... The ALS Therapy Development Institute (ALS TDI) and ... their current research collaboration agreement to test additional ... stop the progression of Amyotrophic Lateral Sclerosis (ALS, ... collaboration is based on encouraging results from early-stage ...
    ... LA JOLLA, CA September 15, 2011 Researchers at ... which certain viruses such as influenza trigger a type of ... This severe immune reactioncalled a "cytokine storm"floods the tiny ... blocking off airways and damaging body tissues and organs. Cytokine ...
    Cached Biology Technology:OptiScan Biomedical Receives CE Mark for OptiScanner Automatic Bedside Glucose Monitoring System 2OptiScan Biomedical Receives CE Mark for OptiScanner Automatic Bedside Glucose Monitoring System 3OptiScan Biomedical Receives CE Mark for OptiScanner Automatic Bedside Glucose Monitoring System 4ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies 2ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies 3Scripps Research team discovers treatable mechanism responsible for often deadly response to flu 2Scripps Research team discovers treatable mechanism responsible for often deadly response to flu 3
    (Date:7/9/2014)... be able to cope with the rising salinity of Arctic ... today is best known for its tundra and polar bear ... 38 million years ago during what is known as the ... temperate forest with brackish water, home to a variety of ... giant tortoises. Much of what is known about the region ...
    (Date:7/9/2014)... be on the verge of an economy driven by methane, ... coal and is undergoing a production boom. It has poised ... research is casting serious doubts over just how climate-friendly it ... News (C&EN), the weekly news magazine of the American ... correspondent at C&EN, explains that when burned as a fuel ...
    (Date:7/9/2014)... Cholinergic inhibitors and N-methyl-D-aspartate receptor antagonists can ... fail to affect irreversible cognitive dysfunction and ... brain. Amyloid beta peptide (Aβ) vaccines reduced ... disease (AD) transgenic mouse model, and significantly ... Cao and his team, First Affiliated Hospital ...
    Breaking Biology News(10 mins):Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
    ... the frontal cortex in adults, researchers have shown that this ... actions. , It has been known for over 100 ... left frontal cortex, he or she often suffers difficulties in ... impairments, it has been difficult for researchers to test the ...
    ... high levels of antibodies against the Epstein-Barr virus, the ... likely to develop multiple sclerosis 15 to 20 years ... will appear in the June 2006 print issue of ... Researchers have long suspected that external factors may influence ...
    ... The cholesterol-lowering medications called statins do not appear to ... to a meta-analysis of previous studies in the January ... that statins reduce the risk of developing cancer, the ... "Statins have been studied in numerous large-scale, randomized, ...
    Cached Biology News:Big hips, big belly? It's in your genes, Joslin-led study shows 2Statins have neutral effect on risk of cancer 2
    ... The IHC Select Immunophosphatase Secondary Detection System ... IHC Select Prediluted Primary Antibody reagents, which ... qualitative identification of antigens by light microscopy ... Secondary Detection System may also be used ...
    ... FLISP Assay with SR-101 Labeled Substrates ... • Accurately measure serine protease activation ... • B-Bridge's FLISP Kits utilize cell-permeable, ... (FLISPs) to measure chymotrypsin-like activity in ...
    From the company that first brought you the chromatin immunoprecipitation (ChIP) kit, a new and improved kit, EZ-ChIP, is now available to make your experiments easier, quicker, and most importantly,...
    The PDS-1000 He Hepta system includes the PDS-1000 He biolistic system and the Hepta adaptor....
    Biology Products: